|
1
|
Iyer L, King CD, Whitington PF, Green MD,
Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition
to the metabolism of irinotecan (CPT-11). Role of uridine
diphosphate glucuronosyltransferase isoform 1A1 in the
glucuronidation of its active metabolite (SN-38) in human liver
microsomes. J Clin Invest. 101:847–854. 1998. View Article : Google Scholar
|
|
2
|
Lokiec F, Canal P, Gay C, Chatelut E,
Armand JP, Roché H, Bugat R, Gonçalvès E and Mathieu-Boué A:
Pharmacokinetics of irinotecan and its metabolites in human blood,
bile, and urine. Cancer Chemother Pharmacol. 36:79–82. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Minami H, Sai K, Saeki M, Saito Y, Ozawa
S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K,
Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A and Saijo N:
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic
polymorphisms in Japanese: roles of UGT1A1*6 and
*28. Parmacogenet Genomics. 17:497–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iyer L, Das S, Janisch L, Wen M, Ramírez
J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ:
UGT1A1*28 polymorphism as a determinant of irinotecan
disposition and toxicity. Pharmacogenomics J. 2:43–47. 2002.
|
|
5
|
Sai K, Saeki M, Saito Y, Ozawa S, Katori
N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K,
Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A,
Shirao K, Yoshida T and Saijo N: UGT1A1 haplotypes associated with
reduced glucuronidation and increased serum bilirubin in
irinotecan-administered Japanese patients with cancer. Clin
Pharmacol Ther. 75:501–515. 2004. View Article : Google Scholar
|
|
6
|
Han JY, Lim HS, Shin ES, Yoo YK, Park YH,
Lee JE, Jang IJ, Lee DH and Lee JS: Comprehensive analysis of
UGT1A1 polymorphisms predictive for pharmacokinetics and treatment
outcome in patients with non-small-cell lung cancer treated with
irinotecan and cisplatin. J Clin Oncol. 24:2237–2244. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glimelius B, Garmo H, Berglund A,
Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H and
Wadelius M: Prediction of irinotecan and 5-fluorouracil toxicity
and response in patients with advanced colorectal cancer.
Pharmacogenomics J. 11:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shulman K, Cohen I, Barnett-Griness O,
Kuten A, Gruber SB, Lejbkowicz F and Rennert G: Clinical
implications of UGT1A1*28 genotype testing in colorectal
cancer patients. Cancer. 117:3156–3162. 2011.PubMed/NCBI
|
|
9
|
Okuyama Y, Hazama S, Nozawa H, Kobayashi
M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K,
Sakamoto J and Mishima H: Prospective phase II study of FOLFIRI for
mCRC in Japan, including the analysis of
UGT1A1*28/*6 polymorphisms. Jpn J Clin Oncol.
41:477–482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamamoto N, Takahashi T, Kunikane H,
Masuda N, Eguchi K, Shibuya M, Takeda Y, Isobe H, Ogura T, Yokoyama
A and Watanabe K: Phase I/II pharmacokinetic and pharmacogenomic
study of UGT1A1 polymorphism in elderly patients with advanced
non-small cell lung cancer treated with irinotecan. Clinical
Pharmacol Ther. 85:149–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akiyama Y, Fujita K, Nagashima F, Yamamoto
W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Araki K,
Ichikawa W, Miya T, Narabayashi M, Kawara K, Sugiyama M, Hirose T,
Ando Y and Sasaki Y: Genetic testing for UGT1A1*28 and
*6 in Japanese patients who receive irinotecan
chemotherapy. Ann Oncol. 19:2089–2094. 2008.PubMed/NCBI
|
|
12
|
Oshita F, Saito H and Yamada K: Feasible
combination chemotherapy with nedaplatin and irinotecan for
patients with non-small cell lung cancer and multiple risk factors.
J Exp Ther Oncol. 6:251–256. 2007.PubMed/NCBI
|
|
13
|
Oshita F, Yamada K, Kato Y, Ikehara M,
Noda K, Tanaka G, Nomura I, Suzuki R and Saito H: Phase I/II study
of escalating doses of nedaplatin in combination with irinotecan
for advanced non-small-cell lung cancer. Cancer Chemother
Pharmacol. 52:73–78. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noda K, Nishiwaki Y, Kawahara M, Negoro S,
Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T,
Yamamoto S and Saijo N; Japan Clinical Oncology Group. Irinotecan
plus cisplatin compared with etoposide plus cisplatin for extensive
small-cell lung cancer. N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanzawa F, Koizumi F, Koh Y, Nakamura T,
Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T and Nishio K: In vitro
synergistic interactions between the cisplatin analogue nedaplatin
and the DNA topoisomerase I inhibitor irinotecan and the mechanism
of this interaction. Clin Cancer Res. 7:202–209. 2001.
|
|
17
|
Matsukuma S, Saito H, Yamada K, Okamoto N,
Ishikawa T, Yoshihara M, Koizume S, Sakuma Y and Miyagi Y: Simple
and precise detection of UGT1A1 polymorphisms with a modified
loop-hybrid mobility shift assay using Cy5-labeled loop probes.
Clin Chim Acta. 412:1668–1672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th edition.
Wiley-Blackwell; NY: 2009
|
|
19
|
Satoh T, Ura T, Yamada Y, Yamazaki K,
Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y,
Koizumi W, Kakeji Y, Ishizuka N, Hyodo I and Sakata Y:
Genotype-directed, dose-finding study of irinotecan in cancer
patients with UGT1A1*28 and/or UGT1A1*6
polymorphisms. Cancer Sci. 102:1868–1873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marcuello E, Páez D, Paré L, Salazar J,
Sebio A, del Rio E and Baiget M: A genotype-directed phase I–IV
dose-finding study of irinotecan in combination with
fluorouracil/leucovorin as first-line treatment in advanced
colorectal cancer. Br J Cancer. 105:53–57. 2011.
|
|
21
|
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG
and McLeod HL: UGT1A1*28 genotype and irinotecan-induced
neutropenia: dose matters. J Natl Cancer Inst. 99:1290–1295.
2007.PubMed/NCBI
|
|
22
|
Hu ZY, Yu Q, Pei Q and Guo C:
Dose-dependent association between UGT1A1*28 genotype
and irinotecan-induced neutropenia: low doses also increase risk.
Clin Cancer Res. 16:3832–3842. 2010.PubMed/NCBI
|
|
23
|
Klastersky J, Paesmans M, Rubenstein EB,
Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B,
Rolston K and Talcott J: The multinational association for
supportive care in cancer risk index. A multinational scoring
system for identifying low-risk febrile neutropenic cancer
patients. J Clin Oncol. 18:3038–3051. 2000.
|
|
24
|
Klastersky J, Paesmans M, Georgala A,
Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M and Barette M:
Outpatient oral antibiotics for febrile neutropenic cancer patients
using a score predictive for complications. J Clin Oncol.
24:4129–4134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu ZY, Yu Q and Zhao YS: Dose-dependent
association between UGT1A1*28 polymorphism and
irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer.
46:1856–1865. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Di Martino MT, Arbitrio M, Leone E, Guzzi
PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D,
Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P and
Tagliaferri P: Single nucleotide polymorphisms of ABCC5 and ABCG1
transporter genes correlate to irinotecan-associated
gastrointestinal toxicity in colorectal cancer patients: a DMET
microarray profiling study. Cancer Biol Ther. 12:780–787. 2011.
|
|
27
|
Bleiberg H and Cvitkovic E:
Characterisation and clinical management of CPT-11
(irinotecan)-induced adverse events: the European perspective. Eur
J Cancer. 32A(Suppl 3): S18–S23. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Merrouche Y, Extra JM, Abigerges D, Bugat
R, Catimel G, Suc E, Marty M, Hérait P, Mahjoubi M and Armand JP:
High dose-intensity of irinotecan administered every 3 weeks in
advanced cancer patients: A feasibility study. J Clin Oncol.
15:1080–1086. 1997.
|
|
29
|
Takeda Y, Kobayashi K, Akiyama Y, Soma T,
Handa S, Kudoh S and Kudo K: Prevention of irinotecan
(CPT-11)-induced diarrhea by oral alkalization combined with
control of defecation in cancer patients. Int J Cancer. 92:269–275.
2001. View Article : Google Scholar : PubMed/NCBI
|
